Bronstein, Gewirtz & Grossman File Class Action Lawsuit Against Geron Corporation
On March 17, 2025, in the United States District Court for the Southern District of New York, Bronstein, Gewirtz & Grossman, LLC, a prominent securities litigation firm, announced the filing of a class action lawsuit against Geron Corporation (“Geron” or “the Company”) (NASDAQ: GERN) and certain of its officers. The lawsuit alleges that Geron and its executives violated the federal securities laws during the Class Period, which spans from June 7, 2024, to February 25, 2025.
Class Definition
The lawsuit seeks to recover damages for all persons and entities that purchased or otherwise acquired Geron securities during the Class Period. The plaintiffs claim that the defendants made false and misleading statements and failed to disclose material information related to the Company’s financial condition and business prospects.
Allegations against Geron
According to the complaint, Geron’s executives made numerous false and misleading statements regarding the Company’s financial performance and its prospects for regulatory approval of its lead product, Imetelstat. These statements were made through various press releases, SEC filings, and public statements made during earnings calls and investor conferences.
Impact on Individual Investors
Individual investors who purchased Geron securities during the Class Period may be eligible to participate in the class action lawsuit. If the plaintiffs are successful, they may be entitled to recover their losses, as well as any damages resulting from the defendants’ alleged wrongdoing. Investors are encouraged to contact Bronstein, Gewirtz & Grossman, LLC to discuss their potential role in the case.
Impact on the World
The filing of this class action lawsuit against Geron could have significant implications for the biotechnology industry as a whole. It highlights the importance of transparency and accuracy in financial reporting, particularly in the context of regulatory approvals for new drugs. The outcome of this lawsuit may set a precedent for future securities litigation cases in the industry.
Conclusion
Bronstein, Gewirtz & Grossman, LLC’s filing of a class action lawsuit against Geron Corporation and certain of its officers alleges securities law violations during the Class Period. The lawsuit seeks to recover damages for all persons and entities that purchased or otherwise acquired Geron securities during that time. The impact of this lawsuit could be far-reaching, with potential consequences for both individual investors and the biotechnology industry as a whole. If you believe you may be affected by this lawsuit, contact Bronstein, Gewirtz & Grossman, LLC to discuss your potential role in the case.
- Bronstein, Gewirtz & Grossman, LLC files class action lawsuit against Geron Corporation and certain officers
- Allegations of securities law violations during the Class Period
- Seeks to recover damages for all persons and entities that purchased Geron securities during the Class Period
- Impact on individual investors and the biotechnology industry
- Contact Bronstein, Gewirtz & Grossman, LLC for more information
